The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Now, the growing buzz around the use of GLP-1 medications like Ozempic to treat alcohol use disorder finally has new clinical ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Northstrive Biosciences has submitted a pre-Investigational New Drug, or pre-IND, meeting request to the FDA for EL-22, a novel myostatin asset ...